Skip to main content

New Cell-Based Screening Company Launches in Pittsburgh

NEW YORK, June 15 (GenomeWeb News) - Lansing Taylor, co-founder of Cellomics and the Pittsburgh Life Sciences Greenhouse, has founded a new company, Cellumen, the company said yesterday in its maiden announcement.


Cellumen, will initially will be headquarted at the PLSG's incubator and will form drug discovery collaborations with pharmaceutical and biotechnology companies using High-Content Screening, a cell-based screening method developed by Cellomics.


Taylor joined with Alan Waggoner from Carnegie Mellon University, who has had a hand in creating other life sciences technologies with Taylor. Taylor and Kenneth Giuliano, a scientist, will be Cellumen's first two employees. The company expects to have a total staff of five to six employees by the end of its first year of operation.


The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.